|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sohda M and Kuwano H: Current status and
future prospects for esophageal cancer treatment. Ann Thorac
Cardiovasc Surg. 23:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jaiswal M, LaRusso NF, Burgart LJ and
Gores GJ: Inflammatory cytokines induce DNA damage and inhibit DNA
repair in cholangiocarcinoma cells by a nitric oxide-dependent
mechanism. Cancer Res. 60:184–190. 2000.PubMed/NCBI
|
|
6
|
McMillan DC: The systemic
inflammation-based Glasgow Prognostic Score: A decade of experience
in patients with cancer. Cancer Treat Rev. 39:534–540. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Smith RA, Bosonnet L, Raraty M, Sutton R,
Neoptolemos JP, Campbell F and Ghaneh P: Preoperative
platelet-lymphocyte ratio is an independent significant prognostic
marker in resected pancreatic ductal adenocarcinoma. Am J Surg.
197:466–472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tomita M, Shimizu T, Ayabe T, Yonei A and
Onitsuka T: Preoperative neutrophil to lymphocyte ratio as a
prognostic predictor after curative resection for non-small cell
lung cancer. Anticancer Res. 31:2995–2998. 2011.PubMed/NCBI
|
|
9
|
Pinato DJ, Shiner RJ, Seckl MJ, Stebbing
J, Sharma R and Mauri FA: Prognostic performance of
inflammation-based prognostic indices in primary operable non-small
cell lung cancer. Br J Cancer. 110:1930–1935. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H, Zhang L, Zhu K, Shi B, Yin Y, Zhu
J, Yue D, Zhang B and Wang C: Prognostic significance of
combination of preoperative platelet count and
neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small
cell lung cancer: Based on a large cohort study. PLoS One.
10:e01264962015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shibutani M, Maeda K, Nagahara H, Ohtani
H, Iseki Y, Ikeya T, Sugano K and Hirakawa K: The prognostic
significance of a postoperative systemic inflammatory response in
patients with colorectal cancer. World J Surg Oncol. 13:1942015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Albayrak S, Zengin K, Tanik S, Atar M,
Unal SH, Imamoglu MA and Gurdal M: Can the neutrophil-to-lymphocyte
ratio be used to predict recurrence and progression of
non-muscle-invasive bladder cancer? Kaohsiung J Med Sci.
32:327–333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong YW, Shi YQ, He LW and Su PZ:
Prognostic significance of neutrophil-to-lymphocyte ratio in rectal
cancer: A meta-analysis. Onco Targets Ther. 9:3127–3134.
2016.PubMed/NCBI
|
|
14
|
Nakamura K, Nagasaka T, Nishida T, Haruma
T, Ogawa C, Kusumoto T, Seki N and Hiramatsu Y: Neutrophil to
lymphocyte ratio in the pre-treatment phase of final-line
chemotherapy predicts the outcome of patients with recurrent
ovarian cancer. Oncol Lett. 11:3975–3981. 2016.PubMed/NCBI
|
|
15
|
Aino H, Sumie S, Niizeki T, Kuromatsu R,
Tajiri N, Nakano M, Satani M, Okamura S, Shimose S, Miyahara K, et
al: The systemic inflammatory response as a prognostic factor for
advanced hepatocellular carcinoma with extrahepatic metastasis. Mol
Clin Oncol. 5:83–88. 2016.PubMed/NCBI
|
|
16
|
Ding PR, An X, Zhang RX, Fang YJ, Li LR,
Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, et al: Elevated preoperative
neutrophil to lymphocyte ratio predicts risk of recurrence
following curative resection for stage IIA colon cancer. Int J
Colorectal Dis. 25:1427–1433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jung MR, Park YK, Jeong O, Seon JW, Ryu
SY, Kim DY and Kim YJ: Elevated preoperative neutrophil to
lymphocyte ratio predicts poor survival following resection in late
stage gastric cancer. J Surg Oncol. 104:504–510. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stotz M, Gerger A, Eisner F, Szkandera J,
Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner
C, et al: Increased neutrophil-lymphocyte ratio is a poor
prognostic factor in patients with primary operable and inoperable
pancreatic cancer. Br J Cancer. 109:416–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, An J, Huang S, He J and Zhang J:
Esophageal cancer-derived microvesicles induce regulatory B cells.
Cell Biochem Funct. 33:308–313. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gholamin M, Moaven O, Memar B, Farshchian
M, Naseh H, Malekzadeh R, Sotoudeh M, Rajabi-Mashhadi MT, Forghani
MN, Farrokhi F, et al: Overexpression and interactions of
interleukin-10, transforming growth factor beta, and vascular
endothelial growth factor in esophageal squamous cell carcinoma.
World J Surg. 33:1439–1445. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen MF, Chen PT, Chen WC, Lu MS, Lin PY
and Lee KD: The role of PD-L1 in the radiation response and
prognosis for esophageal squamous cell carcinoma related to IL-6
and T-cell immunosuppression. Oncotarget. 7:7913–7924.
2016.PubMed/NCBI
|
|
22
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McMillan DC: Systemic inflammation,
nutritional status and survival in patients with cancer. Curr Opin
Clin Nutr Metab Care. 12:223–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zahorec R: Ratio of neutrophil to
lymphocyte counts - rapid and simple parameter of systemic
inflammation and stress in critically ill. Bratisl Lek Listy.
102:5–14. 2001.PubMed/NCBI
|
|
25
|
Higuchi K, Koizumi W, Tanabe S, Sasaki T,
Katada C, Azuma M, Nakatani K, Ishido K, Naruke A and Ryu T:
Current management of esophageal squamous-cell carcinoma in Japan
and other countries. Gastrointest Cancer Res. 3:153–161.
2009.PubMed/NCBI
|
|
26
|
Herskovic A, Martz K, al-Sarraf M,
Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L
and Emami B: Combined chemotherapy and radiotherapy compared with
radiotherapy alone in patients with cancer of the esophagus. N Engl
J Med. 326:1593–1598. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ishida K, Iizuka T, Ando N and Ide H:
Phase II study of chemoradiotherapy for advanced squamous cell
carcinoma of the thoracic esophagus: Nine Japanese institutions
trial. Jpn J Clin Oncol. 26:310–315. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Finn OJ: Cancer immunology. N Engl J Med.
358:2704–2715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yoshimoto Y, Suzuki Y, Mimura K, Ando K,
Oike T, Sato H, Okonogi N, Maruyama T, Izawa S, Noda SE, et al:
Radiotherapy-induced anti-tumor immunity contributes to the
therapeutic efficacy of irradiation and can be augmented by CTLA-4
blockade in a mouse model. PLoS One. 9:e925722014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee Y, Auh SL, Wang Y, Burnette B, Wang Y,
Meng Y, Beckett M, Sharma R, Chin R, Tu T, et al: Therapeutic
effects of ablative radiation on local tumor require CD8+ T cells:
Changing strategies for cancer treatment. Blood. 114:589–595. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takeshima T, Chamoto K, Wakita D, Ohkuri
T, Togashi Y, Shirato H, Kitamura H and Nishimura T: Local
radiation therapy inhibits tumor growth through the generation of
tumor-specific CTL: Its potentiation by combination with Th1 cell
therapy. Cancer Res. 70:2697–2706. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shibata M and Gonda K: Cachexia,
immunological participation. In: Horizons in Cancer ResearchNova
Science. Watanabe HS: Publishers Inc.; New York: pp. 19–32.
2015
|
|
33
|
Shibata M, Nezu T, Kanou H, Abe H,
Takekawa M and Fukuzawa M: Decreased production of interleukin-12
and type 2 immune responses are marked in cachectic patients with
colorectal and gastric cancer. J Clin Gastroenterol. 34:416–420.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shibata M, Nagata Y, Kimura T, Kanou H,
Nezu T, Takekawa M and Fukuzawa M: Elevated serum concentration of
interleukin-1 receptor antagonist (IL-1ra) is correlated to
interleukin-6 and hypoalbuminemia in cachectic patients with
colorectal cancer. Int J Clin Oncol. 5:116–120. 2000. View Article : Google Scholar
|
|
35
|
Shibata M and Takekawa M: Increased serum
concentration of circulating soluble receptor for interleukin-2 and
its effect as a prognostic indicator in cachectic patients with
gastric and colorectal cancer. Oncology. 56:54–58. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ohki S, Shibata M, Gonda K, Machida T,
Shimura T, Nakamura I, Ohtake T, Koyama Y, Suzuki S, Ohto H, et al:
Circulating myeloid-derived suppressor cells are increased and
correlated to immune suppression and hypoalbuminemia in patients
with cancer. Oncol Rep. 28:453–458. 2012.PubMed/NCBI
|
|
37
|
Nakamura I, Shibata M, Gonda K, Yazawa T,
Shimura T, Anazawa T, Suzuki S, Sakurai K, Koyama Y, Ohto H, et al:
Serum levels of vascular endothelial growth factor are increased
and correlate with malnutrition, immunosuppression involving MDSCs
and systemic inflammation in patients with cancer of the digestive
system. Oncol Lett. 5:1682–1686. 2013.PubMed/NCBI
|
|
38
|
Suzuki Y, Mimura K, Yoshimoto Y, Watanabe
M, Ohkubo Y, Izawa S, Murata K, Fujii H, Nakano T and Kono K:
Immunogenic tumor cell death induced by chemoradiotherapy in
patients with esophageal squamous cell carcinoma. Cancer Res.
72:3967–3976. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yoshimoto Y, Kono K and Suzuki Y:
Anti-tumor immune responses induced by radiotherapy. Fukushima J
Med Sci. 61:13–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Garg AD, Galluzzi L, Apetoh L, Baert T,
Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R,
Cirone M, et al: Molecular and translational classifications of
DAMPs in immunologic cell death. Front Immunol. 6:5882015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang RF and Wang HY: Immune targets and
neoantigens for cancer immunotherapy and precision medicine. Cell
Res. 27:11–37. 2017. View Article : Google Scholar : PubMed/NCBI
|
